Eli Lilly Expands Protein Research and Showcases Dermatology Pipeline

Monday, October 5, 2026·Consolidated from 3 sources

Eli Lilly and Company has expanded a collaboration focused on difficult-to-drug proteins. The company is also set to present extensive new data from its dermatology portfolio at an upcoming medical conference. These updates highlight Lilly's ongoing efforts in both novel therapeutic targets and its existing treatment areas.

Eli Lilly and Company announced an expansion of its existing collaboration and license agreement with Gate Bioscience. This partnership aims to target proteins that have historically been challenging to address with conventional drug development methods. The expanded agreement signifies a continued investment in innovative approaches to discover and develop new medicines.

In parallel, Lilly is preparing to share significant new research across its dermatology offerings. The company will feature 21 presentations at the upcoming Fall Clinical 2026 conference. These presentations are intended to highlight progress and new findings in the treatment of chronic skin conditions, underscoring Lilly's commitment to advancing dermatological care.

The recent developments place Eli Lilly at the forefront of both cutting-edge research and the expansion of its clinical portfolio. By pursuing novel targets through strategic partnerships and by presenting comprehensive data on existing therapeutic areas, the company continues to position itself for growth and innovation within the pharmaceutical industry. Coverage today notes the company's active engagement in advancing its broad range of therapeutic programs.

Sources